Dihydrotestosterone

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (4)Enzymes (3)Carriers (1)Transporters (1)

Targets (4)Enzymes (3)Carriers (1)Transporters (1)Biointeractions (4)

Identification

Name

Dihydrotestosterone

Accession Number

DB02901 (EXPT01199)

Type

Small Molecule

Groups

Illicit

Description

A potent androgenic metabolite of testosterone. Dihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid. [PubChem]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

17beta-Hydroxy-5alpha-androstan-3-one

17beta-Hydroxy-5alpha-androstane-3-one

17beta-Hydroxyandrostan-3-one

17β-hydroxy-3-oxo-5α-androstanone

17β-hydroxy-5α-androstan-3-one

4-Dihydrotestosterone

5alpha-Dihydrotestosterone

5α-DHT

Androstanolone

DHT

Dihydrotestosteron

Dihydrotestostérone

Stanolone

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Stanolone acetate	63Z2Y83W8N	1164-91-6	ILCTUFVQFCIIDS-NGFSFWIMSA-N	Details

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Anaboleen	Not Available
Anabolex	Not Available
Anaprotin	Not Available
Andractim	Not Available
Androlone	Not Available
Cristerona MB	Not Available
Neodrol	Not Available
Proteina	Not Available
Protona	Not Available
Stanaprol	Not Available

Brand mixtures

Not Available

Categories

UNII

08J2K08A3Y

CAS number

521-18-6

Weight

Average: 290.4403
Monoisotopic: 290.224580204

Chemical Formula

C₁₉H₃₀O₂

InChI Key

NVKAWKQGWWIWPM-ABEVXSGRSA-N

InChI

InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1

IUPAC Name

(1S,2S,7S,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-5-one

SMILES

[H][[email protected]@]12CC[[email protected]](O)[[email protected]@]1(C)CC[[email protected]@]1([H])[[email protected]@]2([H])CC[[email protected]@]2([H])CC(=O)CC[[email protected]]12C

Pharmacology

Indication

Not Available

Structured Indications

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Androgen receptor	Protein	unknown	Not Available	Human	P10275	details
Estradiol 17-beta-dehydrogenase 1	Protein	unknown	Not Available	Human	P14061	details
Estrogen receptor alpha	Protein	unknown	Not Available	Human	P03372	details
Mineralocorticoid receptor	Protein	unknown	Not Available	Human	P08235	details

Absorption

Bioavailability is very low (0-2%) following oral administration.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Substrate	Enzymes	Product
Dihydrotestosterone	Not Available	11-Oxo-androsterone glucuronide	Details
Dihydrotestosterone	Not Available	3-alpha-Androstanediol glucuronide	Details
Dihydrotestosterone	Not Available	11-beta-Hydroxyandrosterone-3-glucuronide	Details

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Oral LD₅₀ in rat is 7060 mg/kg. Oral LD₅₀ in mouse is 3450 mg/kg.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	16-Bromoepiandrosterone may increase the fluid retaining activities of Dihydrotestosterone.	Investigational
19-norandrostenedione	19-norandrostenedione may increase the fluid retaining activities of Dihydrotestosterone.	Experimental, Illicit
5-androstenedione	5-androstenedione may increase the fluid retaining activities of Dihydrotestosterone.	Experimental, Illicit
Acarbose	Dihydrotestosterone may increase the hypoglycemic activities of Acarbose.	Approved, Investigational
Acenocoumarol	Dihydrotestosterone may increase the anticoagulant activities of Acenocoumarol.	Approved
Acetaminophen	The serum concentration of Dihydrotestosterone can be increased when it is combined with Acetaminophen.	Approved
Afatinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Afatinib.	Approved
Albendazole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Albendazole.	Approved, Vet Approved
Albiglutide	Dihydrotestosterone may increase the hypoglycemic activities of Albiglutide.	Approved
Alclometasone	Alclometasone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Aldosterone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Dihydrotestosterone can be increased when it is combined with Alfentanil.	Approved, Illicit
Alogliptin	Dihydrotestosterone may increase the hypoglycemic activities of Alogliptin.	Approved
Amantadine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Amantadine.	Approved
Amcinonide	Amcinonide may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Aminohippuric acid	The serum concentration of Dihydrotestosterone can be increased when it is combined with Aminohippuric acid.	Approved
Amiodarone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Dihydrotestosterone can be increased when it is combined with Amitriptyline.	Approved
Amlodipine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Amlodipine.	Approved
Amprenavir	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Amsacrine.	Approved
Androstenedione	4-Androstenedione may increase the fluid retaining activities of Dihydrotestosterone.	Experimental, Illicit
Anecortave	Anecortave may increase the fluid retaining activities of Dihydrotestosterone.	Investigational
Astemizole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The serum concentration of Dihydrotestosterone can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Dihydrotestosterone can be increased when it is combined with Atenolol.	Approved
Atorvastatin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Atorvastatin.	Approved
Azelastine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Azelastine.	Approved
Azithromycin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Azithromycin.	Approved
Beclomethasone dipropionate	Beclomethasone dipropionate may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Investigational
Benzocaine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Benzocaine.	Approved
Bepridil	The serum concentration of Dihydrotestosterone can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betamethasone	Betamethasone may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Vet Approved
Biperiden	The serum concentration of Dihydrotestosterone can be increased when it is combined with Biperiden.	Approved
Bosutinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Bosutinib.	Approved
Bromocriptine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Bromocriptine.	Approved, Investigational
Budesonide	Budesonide may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Buprenorphine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The serum concentration of Dihydrotestosterone can be increased when it is combined with Cabazitaxel.	Approved
Caffeine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Caffeine.	Approved
Canagliflozin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Canagliflozin.	Approved
Candesartan	The serum concentration of Dihydrotestosterone can be increased when it is combined with Candesartan.	Approved
Captopril	The serum concentration of Dihydrotestosterone can be increased when it is combined with Captopril.	Approved
Carbamazepine	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carvedilol	The serum concentration of Dihydrotestosterone can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Caspofungin.	Approved
Chloroquine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorpromazine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Cholesterol	The serum concentration of Dihydrotestosterone can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Cholic Acid.	Approved
Ciclesonide	Ciclesonide may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Investigational
Cilazapril	The serum concentration of Dihydrotestosterone can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Cimetidine.	Approved
Ciprofloxacin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ciprofloxacin.	Approved, Investigational
Citalopram	The serum concentration of Dihydrotestosterone can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Clarithromycin.	Approved
Clobetasol	Clobetasol may increase the fluid retaining activities of Dihydrotestosterone.	Investigational
Clobetasol propionate	Clobetasol propionate may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Clocortolone	Clocortolone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Clofazimine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Clomipramine.	Approved, Vet Approved
Clotrimazole	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Clotrimazole.	Approved, Vet Approved
Cobicistat	The serum concentration of Dihydrotestosterone can be increased when it is combined with Cobicistat.	Approved
Colchicine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Colchicine.	Approved
Colforsin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Colforsin.	Experimental
Conestat alfa	Dihydrotestosterone may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).	Approved
Cortisone acetate	Cortisone acetate may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Crizotinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Crizotinib.	Approved
Cyclophosphamide	The serum concentration of Dihydrotestosterone can be increased when it is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	Dihydrotestosterone may increase the hepatotoxic activities of Cyclosporine.	Approved, Investigational, Vet Approved
Cyclosporine	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Daclatasvir	The serum concentration of Dihydrotestosterone can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Dactinomycin.	Approved
Dapagliflozin	Dihydrotestosterone may increase the hypoglycemic activities of Dapagliflozin.	Approved
Dasatinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Daunorubicin.	Approved
Desipramine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Desipramine.	Approved
Desloratadine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Desloratadine.	Approved, Investigational
Desoximetasone	Desoximetasone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Desoxycorticosterone acetate	Desoxycorticosterone acetate may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Desoxycorticosterone Pivalate	Desoxycorticosterone Pivalate may increase the fluid retaining activities of Dihydrotestosterone.	Experimental, Vet Approved
Dexamethasone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	Dexamethasone isonicotinate may increase the fluid retaining activities of Dihydrotestosterone.	Vet Approved
Dextromethorphan	The serum concentration of Dihydrotestosterone can be increased when it is combined with Dextromethorphan.	Approved
Diclofenac	The serum concentration of Dihydrotestosterone can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Dicoumarol	Dihydrotestosterone may increase the anticoagulant activities of Dicoumarol.	Approved
Diflorasone	Diflorasone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Difluocortolone	Difluocortolone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Difluprednate	Difluprednate may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Digoxin	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Digoxin.	Approved
Dihydroergotamine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Dihydroergotamine.	Approved
Diltiazem	The serum concentration of Dihydrotestosterone can be increased when it is combined with Diltiazem.	Approved
Dipyridamole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Dipyridamole.	Approved
Disopyramide	Dihydrotestosterone may increase the hypoglycemic activities of Disopyramide.	Approved
Doxazosin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Dronabinol	The serum concentration of Dihydrotestosterone can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Dronedarone.	Approved
Dulaglutide	Dihydrotestosterone may increase the hypoglycemic activities of Dulaglutide.	Approved
Elbasvir	The serum concentration of Dihydrotestosterone can be increased when it is combined with Elbasvir.	Approved
Empagliflozin	Dihydrotestosterone may increase the hypoglycemic activities of Empagliflozin.	Approved
Enalapril	The serum concentration of Dihydrotestosterone can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enzalutamide	The serum concentration of Dihydrotestosterone can be increased when it is combined with Enzalutamide.	Approved
Equilenin	Equilenin may increase the fluid retaining activities of Dihydrotestosterone.	Experimental
Equilin	Equilin may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Ergonovine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ergotamine.	Approved
Erythromycin	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Erythromycin.	Approved, Vet Approved
Estramustine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Estrone.	Approved
Estrone sulfate	Estrone sulfate may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Ethyl biscoumacetate	Dihydrotestosterone may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etoposide	The serum concentration of Dihydrotestosterone can be increased when it is combined with Etoposide.	Approved
Etravirine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Etravirine.	Approved
Exenatide	Dihydrotestosterone may increase the hypoglycemic activities of Exenatide.	Approved, Investigational
Felodipine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Felodipine.	Approved, Investigational
Fentanyl	The serum concentration of Dihydrotestosterone can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Fidaxomicin.	Approved
fluasterone	fluasterone may increase the fluid retaining activities of Dihydrotestosterone.	Investigational
Fluconazole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Fluconazole.	Approved
Fludrocortisone	Fludrocortisone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Fluindione	Dihydrotestosterone may increase the anticoagulant activities of Fluindione.	Investigational
Flumethasone	Flumethasone may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Vet Approved
Flunisolide	Flunisolide may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Investigational
Fluocinolone Acetonide	Fluocinolone Acetonide may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Investigational, Vet Approved
Fluocinonide	Fluocinonide may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Investigational
Fluocortolone	Fluocortolone may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Withdrawn
Fluorometholone	Fluorometholone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Fluoxetine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of Dihydrotestosterone can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Fluphenazine.	Approved
Fluprednidene	Fluprednidene may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Withdrawn
Fluprednisolone	Fluprednisolone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Flurandrenolide	Flurandrenolide may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Flurazepam	The serum concentration of Dihydrotestosterone can be increased when it is combined with Flurazepam.	Approved, Illicit
Fluticasone furoate	Fluticasone furoate may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Fluticasone propionate	Fluticasone Propionate may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Fluvoxamine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Formestane	Formestane may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Investigational, Withdrawn
Gefitinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Gefitinib.	Approved, Investigational
Genistein	The serum concentration of Dihydrotestosterone can be increased when it is combined with Genistein.	Investigational
Gliclazide	Dihydrotestosterone may increase the hypoglycemic activities of Gliclazide.	Approved
Glimepiride	Dihydrotestosterone may increase the hypoglycemic activities of Glimepiride.	Approved
Glipizide	Dihydrotestosterone may increase the hypoglycemic activities of Glipizide.	Approved
Glyburide	The serum concentration of Dihydrotestosterone can be increased when it is combined with Glyburide.	Approved
Gramicidin D	The serum concentration of Dihydrotestosterone can be increased when it is combined with Gramicidin D.	Approved
Grepafloxacin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Grepafloxacin.	Withdrawn
Haloperidol	The serum concentration of Dihydrotestosterone can be increased when it is combined with Haloperidol.	Approved
HE3286	HE3286 may increase the fluid retaining activities of Dihydrotestosterone.	Investigational
Human C1-esterase inhibitor	Dihydrotestosterone may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).	Approved
Hydrocortisone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Idelalisib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Idelalisib.	Approved
Imatinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Imatinib.	Approved
Imipramine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Imipramine.	Approved
Indinavir	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Indinavir.	Approved
Indomethacin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Indomethacin.	Approved, Investigational
Insulin Aspart	Dihydrotestosterone may increase the hypoglycemic activities of Insulin Aspart.	Approved
Insulin Detemir	Dihydrotestosterone may increase the hypoglycemic activities of Insulin Detemir.	Approved
Insulin Glargine	Dihydrotestosterone may increase the hypoglycemic activities of Insulin Glargine.	Approved
Insulin Glulisine	Dihydrotestosterone may increase the hypoglycemic activities of Insulin Glulisine.	Approved
Insulin Human	Dihydrotestosterone may increase the hypoglycemic activities of Insulin Human.	Approved, Investigational
Insulin Lispro	Dihydrotestosterone may increase the hypoglycemic activities of Insulin Lispro.	Approved
Isavuconazonium	The serum concentration of Dihydrotestosterone can be increased when it is combined with Isavuconazonium.	Approved, Investigational
Istaroxime	Istaroxime may increase the fluid retaining activities of Dihydrotestosterone.	Investigational
Itraconazole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Ketamine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketoconazole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ketoconazole.	Approved, Investigational
Lanreotide	Dihydrotestosterone may increase the hypoglycemic activities of Lanreotide.	Approved
Lansoprazole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Lapatinib.	Approved, Investigational
Levofloxacin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levothyroxine	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Liothyronine	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Liotrix.	Approved
Liraglutide	Dihydrotestosterone may increase the hypoglycemic activities of Liraglutide.	Approved
Lisinopril	The serum concentration of Dihydrotestosterone can be increased when it is combined with Lisinopril.	Approved, Investigational
Lomitapide	The serum concentration of Dihydrotestosterone can be increased when it is combined with Lomitapide.	Approved
Loperamide	The serum concentration of Dihydrotestosterone can be increased when it is combined with Loperamide.	Approved
Lopinavir	The serum concentration of Dihydrotestosterone can be increased when it is combined with Lopinavir.	Approved
Loratadine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Loratadine.	Approved
Losartan	The serum concentration of Dihydrotestosterone can be increased when it is combined with Losartan.	Approved
Lovastatin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Lovastatin.	Approved, Investigational
Lumacaftor	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Lumacaftor.	Approved
Maprotiline	The serum concentration of Dihydrotestosterone can be increased when it is combined with Maprotiline.	Approved
ME-609	ME-609 may increase the fluid retaining activities of Dihydrotestosterone.	Investigational
Mebendazole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mecasermin	Dihydrotestosterone may increase the hypoglycemic activities of Mecasermin.	Approved, Investigational
Medrysone	Medrysone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Mefloquine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Dihydrotestosterone can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Melengestrol	Melengestrol may increase the fluid retaining activities of Dihydrotestosterone.	Vet Approved
Meprobamate	The serum concentration of Dihydrotestosterone can be increased when it is combined with Meprobamate.	Approved, Illicit
Metformin	Dihydrotestosterone may increase the hypoglycemic activities of Metformin.	Approved
Methadone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Methadone.	Approved
Methylprednisolone	Methylprednisolone may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Vet Approved
Metoprolol	The serum concentration of Dihydrotestosterone can be increased when it is combined with Metoprolol.	Approved, Investigational
Mibefradil	The serum concentration of Dihydrotestosterone can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Midazolam.	Approved, Illicit
Mifepristone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Mifepristone.	Approved, Investigational
Miglitol	Dihydrotestosterone may increase the hypoglycemic activities of Miglitol.	Approved
Mitomycin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Mitomycin.	Approved
Mitoxantrone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Mometasone	Mometasone may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Vet Approved
Morphine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Morphine.	Approved, Investigational
Naltrexone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naringenin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Naringenin.	Experimental
Nateglinide	Dihydrotestosterone may increase the hypoglycemic activities of Nateglinide.	Approved, Investigational
NCX 1022	NCX 1022 may increase the fluid retaining activities of Dihydrotestosterone.	Investigational
Nefazodone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Nicardipine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Nicardipine.	Approved
Nifedipine	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Nifedipine.	Approved
Nilotinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Nilotinib.	Approved, Investigational
Nisoldipine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Dihydrotestosterone can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Nitrendipine.	Approved
Norethisterone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Norethisterone.	Approved
Octreotide	Dihydrotestosterone may increase the hypoglycemic activities of Octreotide.	Approved, Investigational
Oleoyl-estrone	Oleoyl estrone may increase the fluid retaining activities of Dihydrotestosterone.	Investigational
Omeprazole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
P-Nitrophenol	The serum concentration of Dihydrotestosterone can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The serum concentration of Dihydrotestosterone can be increased when it is combined with Paclitaxel.	Approved, Vet Approved
Palmitic Acid	The serum concentration of Dihydrotestosterone can be increased when it is combined with Palmitic Acid.	Experimental
Pantoprazole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Pantoprazole.	Approved
Paramethasone	Paramethasone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Paroxetine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Paroxetine.	Approved, Investigational
Pasireotide	Dihydrotestosterone may increase the hypoglycemic activities of Pasireotide.	Approved
Pentamidine	Dihydrotestosterone may increase the hypoglycemic activities of Pentamidine.	Approved
Perindopril	The serum concentration of Dihydrotestosterone can be increased when it is combined with Perindopril.	Approved
Phenindione	Dihydrotestosterone may increase the anticoagulant activities of Phenindione.	Approved
Phenobarbital	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Phenobarbital.	Approved
Phenprocoumon	Dihydrotestosterone may increase the anticoagulant activities of Phenprocoumon.	Approved
Pimozide	The serum concentration of Dihydrotestosterone can be increased when it is combined with Pimozide.	Approved
Pioglitazone	Dihydrotestosterone may increase the hypoglycemic activities of Pioglitazone.	Approved, Investigational
Platelet Activating Factor	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Platelet Activating Factor.	Experimental
Ponatinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ponatinib.	Approved
Posaconazole	The serum concentration of Dihydrotestosterone can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramlintide	Dihydrotestosterone may increase the hypoglycemic activities of Pramlintide.	Approved, Investigational
Prasterone	Prasterone may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Nutraceutical
Prasterone sulfate	dehydroepiandrosterone sulfate may increase the fluid retaining activities of Dihydrotestosterone.	Investigational
Pravastatin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Pravastatin.	Approved
Prazosin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Prazosin.	Approved
Prednicarbate	Prednicarbate may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Prednisolone	Prednisolone may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Vet Approved
Prednisone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Prednisone.	Approved, Vet Approved
Pregnenolone	Pregnenolone may increase the fluid retaining activities of Dihydrotestosterone.	Experimental
Probenecid	The serum concentration of Dihydrotestosterone can be increased when it is combined with Probenecid.	Approved
Progesterone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Promethazine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Promethazine.	Approved
Propafenone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Propafenone.	Approved
Propranolol	The serum concentration of Dihydrotestosterone can be increased when it is combined with Propranolol.	Approved, Investigational
Protriptyline	The serum concentration of Dihydrotestosterone can be increased when it is combined with Protriptyline.	Approved
Quercetin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Quercetin.	Experimental
Quinacrine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Quinacrine.	Approved
Quinidine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Quinidine.	Approved
Quinine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Quinine.	Approved
Ranitidine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ranolazine.	Approved, Investigational
Reboxetine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Regorafenib.	Approved
Repaglinide	Dihydrotestosterone may increase the hypoglycemic activities of Repaglinide.	Approved, Investigational
Reserpine	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Reserpine.	Approved
Rifampicin	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Rifampicin.	Approved
Rilpivirine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Rilpivirine.	Approved
Rimexolone	Rimexolone may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Ritonavir	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Ritonavir.	Approved, Investigational
Rolapitant	The serum concentration of Dihydrotestosterone can be increased when it is combined with Rolapitant.	Approved
Rosiglitazone	Dihydrotestosterone may increase the hypoglycemic activities of Rosiglitazone.	Approved, Investigational
Saquinavir	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Saquinavir.	Approved, Investigational
Saxagliptin	Dihydrotestosterone may increase the hypoglycemic activities of Saxagliptin.	Approved
Scopolamine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Scopolamine.	Approved
Selegiline	The serum concentration of Dihydrotestosterone can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Sertraline	The serum concentration of Dihydrotestosterone can be increased when it is combined with Sertraline.	Approved
Simeprevir	The serum concentration of Dihydrotestosterone can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Simvastatin.	Approved
Sirolimus	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sitagliptin	Dihydrotestosterone may increase the hypoglycemic activities of Sitagliptin.	Approved, Investigational
Sorafenib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Sorafenib.	Approved, Investigational
Spironolactone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Spironolactone.	Approved
St. John's Wort	The serum concentration of Dihydrotestosterone can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Staurosporine.	Experimental
Streptozocin	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Streptozocin.	Approved
Sulfadiazine	Dihydrotestosterone may increase the hypoglycemic activities of Sulfadiazine.	Approved, Vet Approved
Sulfamethoxazole	Dihydrotestosterone may increase the hypoglycemic activities of Sulfamethoxazole.	Approved
Sulfinpyrazone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	Dihydrotestosterone may increase the hypoglycemic activities of Sulfisoxazole.	Approved, Vet Approved
Sumatriptan	The serum concentration of Dihydrotestosterone can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Dihydrotestosterone can be increased when it is combined with Sunitinib.	Approved, Investigational
Tacrine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tamoxifen	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Tamoxifen.	Approved
Taurocholic Acid	The serum concentration of Dihydrotestosterone can be increased when it is combined with Taurocholic Acid.	Experimental
Telmisartan	The serum concentration of Dihydrotestosterone can be increased when it is combined with Telmisartan.	Approved, Investigational
Temsirolimus	The serum concentration of Dihydrotestosterone can be increased when it is combined with Temsirolimus.	Approved
Terazosin	The serum concentration of Dihydrotestosterone can be increased when it is combined with Terazosin.	Approved
Terfenadine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Terfenadine.	Withdrawn
Tesmilifene	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Testosterone.	Approved, Investigational
Ticagrelor	The serum concentration of Dihydrotestosterone can be increased when it is combined with Ticagrelor.	Approved
Tixocortol	Tixocortol may increase the fluid retaining activities of Dihydrotestosterone.	Approved
Tolazamide	Dihydrotestosterone may increase the hypoglycemic activities of Tolazamide.	Approved
Tolbutamide	Dihydrotestosterone may increase the hypoglycemic activities of Tolbutamide.	Approved
Tolvaptan	The serum concentration of Dihydrotestosterone can be increased when it is combined with Tolvaptan.	Approved
Trazodone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Trazodone.	Approved, Investigational
Triamcinolone	Triamcinolone may increase the fluid retaining activities of Dihydrotestosterone.	Approved, Vet Approved
Trifluoperazine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Trimipramine.	Approved
Venlafaxine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Venlafaxine.	Approved
Verapamil	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Verapamil.	Approved
Vinblastine	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Vinorelbine.	Approved, Investigational
Warfarin	Dihydrotestosterone may increase the anticoagulant activities of Warfarin.	Approved
Zimelidine	The serum concentration of Dihydrotestosterone can be increased when it is combined with Zimelidine.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

A. Glenn Braswell, Aftab J. Ahmed, "Composition for inhibiting production of dihydrotestosterone to treat benign prostate hyperplasia." U.S. Patent US6264996, issued October, 1996.

US6264996

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB02961
KEGG Drug	D07456
KEGG Compound	C03917
ChemSpider	10189
BindingDB	18161
ChEBI	16330
ChEMBL	CHEMBL27769
HET	DHT
Wikipedia	Dihydrotestosterone

ATC Codes

A14AA01 — Androstanolone

G03BB02 — Androstanolone

AHFS Codes

Not Available

PDB Entries

1D2S

FDA label

Not Available

MSDS

Download (111 KB)

Clinical Trials

Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	181 °C	PhysProp
water solubility	525 mg/mL (at 25 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP	3.55	HANSCH,C ET AL. (1995)

Predicted Properties

Property	Value	Source
Water Solubility	0.00998 mg/mL	ALOGPS
logP	3.37	ALOGPS
logP	3.41	ChemAxon
logS	-4.5	ALOGPS
pKa (Strongest Acidic)	19.38	ChemAxon
pKa (Strongest Basic)	-0.88	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	37.3 Å²	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	83.6 m³·mol^-1	ChemAxon
Polarizability	34.69 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9818
Caco-2 permeable	+	0.8846
P-glycoprotein substrate	Substrate	0.57
P-glycoprotein inhibitor I	Non-inhibitor	0.5631
P-glycoprotein inhibitor II	Non-inhibitor	0.846
Renal organic cation transporter	Non-inhibitor	0.7884
CYP450 2C9 substrate	Non-substrate	0.7715
CYP450 2D6 substrate	Non-substrate	0.93
CYP450 3A4 substrate	Substrate	0.7314
CYP450 1A2 substrate	Non-inhibitor	0.6853
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.971
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.8546
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9647
Ames test	Non AMES toxic	0.9414
Carcinogenicity	Non-carcinogens	0.9182
Biodegradation	Not ready biodegradable	0.9686
Rat acute toxicity	1.9757 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9444
hERG inhibition (predictor II)	Non-inhibitor	0.576

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Download (11.2 KB)

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
GC-MS	GC-MS Spectrum - EI-B	splash10-015c-8970000000-ef0c6a4fd9c52be30284	View in MoNA
GC-MS	GC-MS Spectrum - EI-B	splash10-001l-1790000000-60cff73adc796876d469	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available
MS	Mass Spectrum (Electron Ionization)	splash10-000x-9870000000-f6d80b2a53942c9af50b	View in MoNA
1D NMR	13C NMR Spectrum	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.

Kingdom

Organic compounds

Super Class

Lipids and lipid-like molecules

Class

Steroids and steroid derivatives

Sub Class

Androstane steroids

Direct Parent

Androgens and derivatives

Alternative Parents

3-oxo-5-alpha-steroids / 17-hydroxysteroids / Secondary alcohols / Cyclic ketones / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives

Substituents

Androgen-skeleton / 3-oxosteroid / 3-oxo-5-alpha-steroid / 17-hydroxysteroid / Oxosteroid / Hydroxysteroid / Cyclic alcohol / Cyclic ketone / Secondary alcohol / Ketone

Molecular Framework

Aliphatic homopolycyclic compounds

External Descriptors

3-oxo steroid, 17beta-hydroxy steroid, 17beta-hydroxyandrostan-3-one (CHEBI:16330 ) / C19 steroids (androgens) and derivatives, Androstane and derivatives, Androgens (C03917 ) / C19 steroids (androgens) and derivatives (LMST02020042 )

Targets

Details

1. Androgen receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Zinc ion binding
Specific Function:: Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
Gene Name:: AR
Uniprot ID:: P10275
Uniprot Name:: Androgen receptor
Molecular Weight:: 98987.9 Da

References

Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM: Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem. 2007 Aug 31;282(35):25801-16. Epub 2007 Jun 25. [PubMed:17591767 ]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Details

2. Estradiol 17-beta-dehydrogenase 1

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Testosterone dehydrogenase (nad+) activity
Specific Function:: Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH.
Gene Name:: HSD17B1
Uniprot ID:: P14061
Uniprot Name:: Estradiol 17-beta-dehydrogenase 1
Molecular Weight:: 34949.715 Da

Details

3. Estrogen receptor alpha

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Zinc ion binding
Specific Function:: Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:: ESR1
Uniprot ID:: P03372
Uniprot Name:: Estrogen receptor
Molecular Weight:: 66215.45 Da

References

Kojima H, Iida M, Katsura E, Kanetoshi A, Hori Y, Kobayashi K: Effects of a diphenyl ether-type herbicide, chlornitrofen, and its amino derivative on androgen and estrogen receptor activities. Environ Health Perspect. 2003 Apr;111(4):497-502. [PubMed:12676605 ]

Details

4. Mineralocorticoid receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Zinc ion binding
Specific Function:: Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:: NR3C2
Uniprot ID:: P08235
Uniprot Name:: Mineralocorticoid receptor
Molecular Weight:: 107066.575 Da

References

Takeda AN, Pinon GM, Bens M, Fagart J, Rafestin-Oblin ME, Vandewalle A: The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor. Mol Pharmacol. 2007 Feb;71(2):473-82. Epub 2006 Nov 14. [PubMed:17105867 ]

Enzymes

Details

1. Cholesterol side-chain cleavage enzyme, mitochondrial

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:: Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:: CYP11A1
Uniprot ID:: P05108
Uniprot Name:: Cholesterol side-chain cleavage enzyme, mitochondrial
Molecular Weight:: 60101.87 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

2. Steroid 17-alpha-hydroxylase/17,20 lyase

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid 17-alpha-monooxygenase activity
Specific Function:: Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
Gene Name:: CYP17A1
Uniprot ID:: P05093
Uniprot Name:: Steroid 17-alpha-hydroxylase/17,20 lyase
Molecular Weight:: 57369.995 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

3. Cytochrome P450 19A1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxygen binding
Specific Function:: Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:: CYP19A1
Uniprot ID:: P11511
Uniprot Name:: Aromatase
Molecular Weight:: 57882.48 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Details

1. Sex hormone-binding globulin

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Androgen binding
Specific Function:: Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.
Gene Name:: SHBG
Uniprot ID:: P04278
Uniprot Name:: Sex hormone-binding globulin
Molecular Weight:: 43778.755 Da

References

Metzger J, Schnitzbauer A, Meyer M, Soder M, Cuilleron CY, Hauptmann H, Huber E, Luppa PB: Binding analysis of 1alpha- and 17alpha-dihydrotestosterone derivatives to homodimeric sex hormone-binding globulin. Biochemistry. 2003 Nov 25;42(46):13735-45. [PubMed:14622020 ]
Hauptmann H, Metzger J, Schnitzbauer A, Cuilleron CY, Mappus E, Luppa PB: Syntheses and ligand-binding studies of 1 alpha- and 17 alpha-aminoalkyl dihydrotestosterone derivatives to human sex hormone-binding globulin. Steroids. 2003 Sep;68(7-8):629-39. [PubMed:12957668 ]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Uniprot Name:: Multidrug resistance protein 1
Molecular Weight:: 141477.255 Da

References

Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer LD, Nelson CC: P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90. [PubMed:14991868 ]

Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:58

Structure for DB02901 (Dihydrotestosterone)

Targets

References

References

References

Enzymes

References

References

References

Carriers

References

Transporters

References